BCL6 is often implicated in the regulation of apoptosis in melanoma cells, making it a valuable target for therapy. By using anti-BCL6 antibodies conjugated to liposomes, researchers aim to induce apoptosis selectively in melanoma cells while minimizing damage to healthy tissues. This method enhances the therapeutic index and could improve the outcomes of traditional chemotherapy or immunotherapy. Early studies indicate that this targeted approach may lead to a reduced tumor burden in melanoma models.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-1279z | Mouse Anti-BCL6 Recombinant Antibody (clone 21C8) | FC, IF, IHC, WB | Mouse IgG1, κ |
MOB-0263MZ | Mouse Anti-BCL6 Recombinant Antibody (clone QG-B7p) | IHC | Mouse IgG1 |
MRO-0163-CN | Rabbit Anti-BCL6 Recombinant Antibody (clone JB18-48) | WB | Rabbit IgG |
HPAB-1961-FY | Human Anti-BCL6 Recombinant Antibody (clone GN15) | FC | Human IgG, λ |
HPAB-1962-FY | Human Anti-BCL6 Recombinant Antibody (clone GN05) | FC | Human IgG, κ |
There are currently no Customer reviews or questions for VS-1024-FY164. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.